©The Author(s) 2026.
World J Gastroenterol. Feb 28, 2026; 32(8): 114268
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.114268
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.114268
Figure 4 Progression-free survival curve.
A: Progression-free survival curve based on the neutrophil-to-lymphocyte ratio; B: Progression-free survival curve based on somatostatin analog use. Hazards ratio values were derived from Kaplan-Meier calculations. HR: Hazards ratio; CI: Confidence interval; NLR: Neutrophil-to-lymphocyte ratio; SSA: Somatostatin analog.
- Citation: Yang ZL, Wang HK, Liu Y, Dou LZ, Zhang YM, Ng HI, He S, Chi YB, Wang GQ. Progression after endoscopic treatment for type I gastric neuroendocrine tumors: A single-center retrospective study. World J Gastroenterol 2026; 32(8): 114268
- URL: https://www.wjgnet.com/1007-9327/full/v32/i8/114268.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i8.114268